1996
DOI: 10.1097/00042737-199603000-00008
|View full text |Cite
|
Sign up to set email alerts
|

Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohnʼs disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
36
1
2

Year Published

1997
1997
2019
2019

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 90 publications
(39 citation statements)
references
References 0 publications
0
36
1
2
Order By: Relevance
“…Severe endoscopic recurrence was however recorded less frequently in the treatment group (14%) than in the placebo group (50%; p < 0.002). Mesalazine (Pentasa, 3,000 mg/day, 106 patients) introduced 15 days after ‘curative’ resection did not reduce the rate of endoscopic recurrence at 3 months compared to placebo (50 vs. 63%, p = 0.16) [34]. …”
Section: Treatmentmentioning
confidence: 99%
“…Severe endoscopic recurrence was however recorded less frequently in the treatment group (14%) than in the placebo group (50%; p < 0.002). Mesalazine (Pentasa, 3,000 mg/day, 106 patients) introduced 15 days after ‘curative’ resection did not reduce the rate of endoscopic recurrence at 3 months compared to placebo (50 vs. 63%, p = 0.16) [34]. …”
Section: Treatmentmentioning
confidence: 99%
“…2 In Crohn's ileocolitis, 5-ASA was better than placebo in one trial, 2 and was not signi®cantly different from placebo in seven. 3,6,8,10,12,15,17 Third, of seven trials in which recurrence rates in previously operated patients are reported, 5-ASA was better than placebo in six 3,8,9,13,14,16 and worse in one. 4 Other discrepancies emerge when one examines the relationship between duration of remission prior to enrolment and recurrence rate.…”
Section: Discussionmentioning
confidence: 97%
“…This metaanalysis was later updated to include the study by Lochs et al 35 The results still showed a significant benefit in favor of mesalamine, although reduced from the initial estimate (Ϫ10.0%, 95% CI: Ϫ16.9% to Ϫ3.2%, P ϭ 0.0041), with a number needed to treat of 10 to prevent 1 relapse. 40 The results of the meta-analysis do not include the more recent study by Hanauer et al 34 from 2004 and excluded the study by Florent et al 33 because of a short study duration.…”
Section: Mesalaminementioning
confidence: 99%